News
FDA clears iHealthScreen's iPredict-DR for automated diabetic retinopathy screening
iHealthScreen received 510(k) clearance (K253704) for iPredict-DR, an AI-powered software that detects more-than-mild diabetic retinopathy in adults with diabetes from color fundus images captured by an iCare DRSplus camera. The device is designed for use by minimally skilled healthcare workers, making it a point-of-care screening tool that can reach patients in primary care and endocrinology settings without requiring a retina specialist.
- FDA
- ophthalmology
- diabetic-retinopathy
- screening
- 510k
Diabetic retinopathy is the canonical example of a condition where AI screening creates unambiguous value: it affects about 34% of people with diabetes in the U.S., it is largely asymptomatic until advanced, and the treatment window that determines whether vision is preserved or lost is precisely the window that better screening opens. The challenge has always been getting the right imaging equipment and reading expertise into the settings where diabetic patients actually receive care — primary care offices and endocrinology practices, not ophthalmology clinics.
iPredict-DR addresses the deployment problem directly. By pairing the AI with the iCare DRSplus — a non-mydriatic fundus camera designed to be operated by medical assistants without dilation — the system moves the screening decision out of specialist workflows and into routine diabetes management visits. The 510(k) clearance for detecting “more-than-mild” diabetic retinopathy means iPredict-DR is calibrated for the referral threshold: flag patients who need an ophthalmologist, pass the rest. That is exactly what a primary care office needs.
The competitive landscape is relevant context. IDx-DR (now Lumify from Welch Allyn/Baxter) received the first FDA authorization for autonomous AI diabetic retinopathy screening in 2018. In the eight years since, the category has grown but deployment has remained uneven — IDx-DR requires specific Topcon cameras, and neither the device cost nor the workflow overhead has driven mass adoption at small independent practices. iHealthScreen’s choice of the iCare DRSplus as the anchor hardware is a bet that a different camera ecosystem unlocks a different distribution channel.
Watch for the real test to be payer coverage and reimbursement coding. FDA clearance is a necessary but not sufficient condition for the preventive screening case to close at a primary care practice. If CMS adds a reimbursable CPT code for AI-assisted diabetic retinopathy screening with iPredict-DR — as it has been signaling for autonomous AI diagnostic reads — adoption will accelerate meaningfully.
Related coverage: FDA & devices topic.
Primary source: Read the full original on Healio ↗